Zaidi, Moosa H. http://orcid.org/0000-0003-1788-6306
Rosenblatt, Tatiana R.
Al-Moujahed, Ahmad
Vail, Daniel
Callaway, Natalia F. http://orcid.org/0000-0002-9788-9605
Nguyen, Quan Dong http://orcid.org/0000-0002-6024-8441
Moshfeghi, Darius M. http://orcid.org/0000-0003-2254-292X
Funding for this research was provided by:
Österreichische Agentur für Internationale Mobilität und Kooperation in Bildung, Wissenschaft und Forschung
Article History
Received: 18 January 2022
Revised: 2 February 2022
Accepted: 2 February 2022
First Online: 25 February 2022
Competing interests
: DMM reported serving as a consultant for Akceso Advisors AG, Alcon, Alexion, CMEOutfitters.com, Congruence Medical Solutions, M3 Global Research, Northwell Health, Novartis Pharmaceuticals, Inc, Ocular Surgery News, Praxis UNS, Inc, Prime Medical Education, Retina Today/Pentavision, Shapiro Law Group, SLACK, Inc, University of Miami, and Vindico; serving as a principal investigator for Apellis and Regeneron; being a founder of dSentz, Inc, Linc, Placid0, Inc, Pr3vent, Promisight, Inc, and Versl, Inc; holding equity in 1800Contacts, dSentz Inc, Grand Legend Technology, Ltd, Linc, Placid0, Inc, Pr3vent, Promisight, Inc, Pykus, Versl, Inc, and Visunex; serving on the board of directors of 1800Contacts, dSentz Inc, Linc, Placid0, Inc, Pr3vent, and Promisight, Inc; serving on the scientific advisory board of Akebia, Allegro, Clinical Trials Resource Group, Irenix, Pykus, and Visunex; serving as a steering committee member of Bayer Pharma AG, Iconic Therapeutics, and Regeneron; serving on a drug safety monitoring board for Novartis Pharmaceuticals, Inc, receiving grant support from Genentech, Research to Prevent Blindness, Inc, and NEI P30-EY026877; and receiving speaking honoraria from VRS. NFC reported serving as a consultant for Genentech, holding equity in Genentech, and employment by Genentech. The other authors have no conflicts of interest to disclose.